论文部分内容阅读
目的评价普拉克索联合恩他卡朋对帕金森病非运动症状患者的血清同型半胱氨酸及血尿酸水平影响。方法入选66例帕森金病非运动症患者,分为试验组和对照组,每组33例。对照组口服恩他卡朋,最初剂量为0.1 g,试验组在对照组基础上加用普拉克索,最初剂量为0.375 mg,3周为一个疗程。观察2组患者治疗前和治疗半年后的血清同型半胱氨酸、血尿酸水平及相关情况评分,比较2组患者治疗后的药物疗效及不良反应情况。结果治疗后,试验组总临床疗效(93.94%)显著高于对照组(78.79%)。试验组的血清同型半胱氨酸水平(9.31±0.78)μmol·L-1显著低于对照组(15.46±1.02)μmol·L-1,血尿酸水平(302.45±58.89)μmol·L-1显著高于对照组(269.33±40.59)μmol·L-1。试验组异动时间、开期时间、关期时间显著优于对照组(P<0.05)。试验组相关评分改善效果显著优于对照组(P均<0.05)。结论普拉克索联合恩他卡朋治疗帕森金病非运动症状能明显改善患者的血清同型半胱氨酸及血尿酸水平,不良反应少,疗效良好。
Objective To evaluate the effect of pramipexole combined with entecavir on serum homocysteine and serum uric acid in patients with non-motor symptoms of Parkinson’s disease. Methods Sixty-six patients with Parkinson’s disease non-motor disorder were enrolled and divided into experimental group and control group, with 33 cases in each group. The control group oral entecavir, the initial dose of 0.1 g, the experimental group in the control group based on the use of pramipexole, the initial dose of 0.375 mg, 3 weeks for a course of treatment. Serum homocysteine, serum uric acid levels and related status scores were observed before treatment and six months after treatment in two groups of patients, and the efficacy and adverse reactions of the two groups after treatment were compared. Results After treatment, the total clinical efficacy (93.94%) in the experimental group was significantly higher than that in the control group (78.79%). The level of serum homocysteine (9.31 ± 0.78) μmol·L-1 in the experimental group was significantly lower than that in the control group (15.46 ± 1.02 μmol·L-1) and the level of serum uric acid (302.45 ± 58.89 μmol·L-1) Higher than the control group (269.33 ± 40.59) μmol·L-1. Test group transaction time, opening time, off-time was significantly better than the control group (P <0.05). The improvement effect of the relevant score of the experimental group was significantly better than that of the control group (all P <0.05). Conclusions Pramipexole combined with entecavir can significantly improve the level of serum homocysteine and uric acid in patients with Parkinson’s disease. The adverse reaction is less and the curative effect is good.